Efficacy of gefitinib and erlotinib in non-small-cell lung carcinoma
AA Laitupa, L Wulandari - New Armenian Medical Journal, 2019 - repository.unair.ac.id
1. Artikel membahas tentang terapi kanker paru yaitu untuk menggali tingkat efektivitas pada
dua jenis terapi pengobatan pasien kanker paru NSCLC berdasarkan penelitian-penelitian …
dua jenis terapi pengobatan pasien kanker paru NSCLC berdasarkan penelitian-penelitian …
药物相关性分子靶标检测在指导Ⅲ-Ⅳ 期儿童神经母细胞瘤治疗中的初步经验
王奕， 吴晔明， 张弛， 吕凡， 袁晓军， 蒋马伟， 李玉华… - 中华小儿外科 …, 2016 - cqvip.com
目的探讨药物相关性分子靶标检测在儿童神经母细胞瘤个体化治疗中的作用和意义. 方法2011
年4 月至2013 年4 月间在上海交通大学医学院附属新华医院诊治的13 例儿童神经母细胞瘤患儿 …
年4 月至2013 年4 月间在上海交通大学医学院附属新华医院诊治的13 例儿童神经母细胞瘤患儿 …
It is too Early to Say NO IMMUNOTHERAPY for EGFR‐Mutant NSCLC Patients
DAN YAN - 2023 - preprints.org
EGFR tyrosine kinase inhibitors (TKIs) are the preferred initial treatment for non-small cell
lung cancer (NSCLC) patients harboring EGFR mutations. However, remission is transient …
lung cancer (NSCLC) patients harboring EGFR mutations. However, remission is transient …
Structural optimization of diphenylpyrimidine scaffold as potent and selective epidermal growth factor receptor inhibitors against L858R/T790M resistance mutation in …
Y Yi, L Wang, D Zhao, S Huang, C Wang… - Chemical Biology & …, 2018 - Wiley Online Library
A new class of thiodiphenylpyrimidine analogs (Thio‐DPPY) were synthesized as potent
and selective EGFR T790M inhibitors to overcome gefitinib resistance in nonsmall cell lung …
and selective EGFR T790M inhibitors to overcome gefitinib resistance in nonsmall cell lung …
Quantifying protein expression and activity complements genetics to optimize the use of targeted therapies in precision oncology
C Sobsey - 2023 - escholarship.mcgill.ca
La voie biochimique de la phosphatidylinositol-3-kinase (PI3K) est l'une des voies les plus
souvent dérégulées dans le cancer et la cible de nombreux nouveaux médicaments. Le …
souvent dérégulées dans le cancer et la cible de nombreux nouveaux médicaments. Le …
Quantitative and qualitative assessment of real world data comparative effectiveness research of systemic therapies in lung oncology: a systematic review
BJM Peters, VEMT Janssen, FM Schramel… - Cancer …, 2016 - Elsevier
Introduction The growing interest in comparative effectiveness research (CER) based on
data from routine clinical practice also extends towards lung oncology. Although CER …
data from routine clinical practice also extends towards lung oncology. Although CER …
Gefitinib: an “orphan” drug for non-small cell lung cancer
Introduction: The discovery of sensitizing mutations in epidermal growth factor receptor
(EGFR) and the rapid development of EGFR tyrosine kinase inhibitors (TKIs) have …
(EGFR) and the rapid development of EGFR tyrosine kinase inhibitors (TKIs) have …
Treatment patterns and healthcare resource utilization and payments in patients with lung cancer in the Texas Medicaid program
X Ma - 2023 - repositories.lib.utexas.edu
The economic burden associated with the treatment of lung cancer is substantial. With the
introduction of targeted therapy and immunotherapy, treatment options for lung cancer …
introduction of targeted therapy and immunotherapy, treatment options for lung cancer …
[PDF][PDF] C-reactive protein to albumin ratio as prognostic markers in patients with advanced non-small-cell lung cancers treated with tyrosine kinase inhibitors [J]
Y Lei, J Wu, W Guo, Y He, T Hu, W Li - Int J Clin Exp Med, 2018 - e-century.us
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) have demonstrated
a dramatic response rate and prolonged progression free survival (PFS) in patients …
a dramatic response rate and prolonged progression free survival (PFS) in patients …
[PDF][PDF] Retrospective analysis of gefitinib and erlotinib in EGFR-mutated non-small-cell lung cancer patients
C Pui, C Gregory, Z Lunqing, LI Long… - Journal of Lung …, 2017 - lungdiseasesjournal.com
Objective: The objective of this study was to compare the efficacies of gefitinib and erlotinib
in treating EGFR-mutated non-small-cell lung cancer (NSCLC) patients. Methods: 319 EGFR …
in treating EGFR-mutated non-small-cell lung cancer (NSCLC) patients. Methods: 319 EGFR …